| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/02/2000 | DE19838705A1 Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one New dihydro- (1,2,3) triazolo [4,5-d] pyrimidin-7-one |
| 03/02/2000 | CA2342162A1 Drug targeting |
| 03/02/2000 | CA2341370A1 Novel substituted triazole compounds |
| 03/02/2000 | CA2341357A1 Quinazoline derivatives and pharmaceutical applications therof |
| 03/02/2000 | CA2340785A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 03/02/2000 | CA2340466A1 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |
| 03/02/2000 | CA2340277A1 Human rna-associated proteins |
| 03/02/2000 | CA2339800A1 Gene therapy for regulating smooth muscle cell tone |
| 03/02/2000 | CA2339775A1 Vitamin d3 mimics |
| 03/01/2000 | EP0982300A2 Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| 03/01/2000 | EP0981514A1 3-epi vitamin d2 compounds and uses thereof |
| 03/01/2000 | EP0981351A1 Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder |
| 03/01/2000 | EP0513387B1 Thiazole derivatives as active oxygen inhibitors |
| 03/01/2000 | CN1245709A Chinese medicine for curing lithiasis |
| 02/29/2000 | US6031000 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| 02/29/2000 | US6030946 Reversible cysteine protease inhibitors |
| 02/29/2000 | US6030945 Apo-2 ligand |
| 02/29/2000 | US6030835 Methods and composition for identifying group a streptococcus |
| 02/29/2000 | US6030825 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 02/29/2000 | US6030617 Use of growth differentiation factor-9 (GDF-9) to inhibit oocyte maturation |
| 02/24/2000 | WO2000009691A2 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
| 02/24/2000 | WO2000009552A1 Secreted proteins and polynucleotides encoding them |
| 02/24/2000 | WO2000009503A1 Integrin receptor antagonists |
| 02/24/2000 | WO2000009496A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 02/24/2000 | WO2000009489A1 New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |
| 02/24/2000 | WO2000009142A1 Methods for treatment of neurological disorders |
| 02/24/2000 | WO2000009128A1 Treatment of fecal incontinence |
| 02/24/2000 | WO1999062538A8 Alpha-keto oxadiazoles as serine protease inhibitors |
| 02/24/2000 | CA2340259A1 Treatment of fecal incontinence |
| 02/24/2000 | CA2340258A1 Methods for treatment of neurological disorders |
| 02/24/2000 | CA2340167A1 New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |
| 02/24/2000 | CA2339047A1 Secreted proteins and polynucleotides encoding them |
| 02/24/2000 | CA2338878A1 Integrin receptor antagonists |
| 02/23/2000 | EP0980369A1 Sulfonamides for treatment of endothelin-mediated disorders |
| 02/23/2000 | EP0980368A1 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands |
| 02/23/2000 | EP0980252A1 Therapies for acute renal failure |
| 02/23/2000 | EP0980244A1 Use of quinazoline compounds for the treatment of polycystic kidney disease |
| 02/23/2000 | CN1049660C Benzopyran compounds, process for their preparation and pharmaceutical compositions containing them |
| 02/23/2000 | CN1049654C Piperazine derivatives and medicine composition containing same and use thereof |
| 02/22/2000 | US6028106 Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| 02/22/2000 | US6028051 Administering single dose of lysostaphin analogue and lysostaphin for treating endocarditis, bacterimia, kidney infection, lung infection, skin infection, bone infection, burn wound infections, infection of prosthetic devices |
| 02/22/2000 | US6027927 Human trk receptors and neurotrophic factor inhibitors |
| 02/17/2000 | WO2000008141A2 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008140A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008046A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |
| 02/17/2000 | WO2000007997A1 IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS |
| 02/17/2000 | WO2000007629A2 Peg-urate oxidase conjugates and use thereof |
| 02/17/2000 | WO2000007624A2 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 02/17/2000 | WO2000007604A1 Prostate formula |
| 02/17/2000 | WO2000007581A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/17/2000 | WO1999065942A8 Cyclic somatostatin analogs |
| 02/17/2000 | WO1999063931A3 Peptidyl-prolyl cis-trans isomerase inhibitors and uses therefor |
| 02/17/2000 | WO1999054310A3 New substituted amides, their production and their use |
| 02/17/2000 | WO1999053036A9 Ste20-related protein kinases |
| 02/17/2000 | DE19836697A1 New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes |
| 02/17/2000 | DE19836044A1 New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer |
| 02/17/2000 | CA2339638A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |
| 02/17/2000 | CA2339416A1 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339340A1 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339086A1 Dna replication- and repair-associated proteins |
| 02/17/2000 | CA2338594A1 Imidazoles and related compounds as .alpha.1a agonists |
| 02/17/2000 | CA2338035A1 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/16/2000 | EP0979869A1 Short oligonucleotides for the inhibition of VEGF expression |
| 02/16/2000 | EP0979289A1 Human lysophospholipase |
| 02/16/2000 | EP0979097A1 Hgf for treating acute renal failure |
| 02/16/2000 | CN1244873A Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 02/16/2000 | CN1244870A Tissue specific expression of retinoblastoma protein |
| 02/16/2000 | CN1244862A Endothelin antagonists: N-[[2'-[[4,5-dimethyl-3-isoxazolyl) amino] sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl] methyl] |
| 02/16/2000 | CN1244402A Supporting for treating prostate disease |
| 02/16/2000 | CN1049335C Medicinal use of benzothiophene compounds |
| 02/15/2000 | US6025494 Tetracyclic derivatives, process of preparation and use |
| 02/15/2000 | US6025381 3,4-(diphenyl)chromans |
| 02/15/2000 | US6025379 Methods of treating or preventing interstitial cystitis |
| 02/15/2000 | US6025344 Certain dioic acid derivatives useful as NAALADase inhibitors |
| 02/15/2000 | US6025166 Human trk receptors and neurotrophic factor inhibitors |
| 02/15/2000 | CA2058398C 1,4 benzothiazine-2-acetic acid derivatives, processes for production thereof |
| 02/10/2000 | WO2000006743A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 02/10/2000 | WO2000006730A2 Human cytoskeletal proteins |
| 02/10/2000 | WO2000006716A1 Growth differentiation factor-11 |
| 02/10/2000 | WO2000006709A1 Human protein kinase h2lau20 |
| 02/10/2000 | WO2000006589A1 Prostate derived ets factor |
| 02/10/2000 | WO2000006580A1 Pyridobenzothiazine derivatives and process for producing the same |
| 02/10/2000 | WO2000006578A1 Pyridobenzoxazine derivatives and process for producing the same |
| 02/10/2000 | WO2000006572A1 Bensoquinolizine derivatives and process for producing the same |
| 02/10/2000 | WO2000006571A1 Pyrroloquinoline derivatives and process for producing the same |
| 02/10/2000 | WO2000006567A1 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine |
| 02/10/2000 | WO2000006561A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 02/10/2000 | WO2000006544A1 Cyclic amine derivatives and process for the preparation thereof |
| 02/10/2000 | WO2000006254A2 Non-imidazole alkylamines as histamine h3-receptor ligands and their therapeutic applications |
| 02/10/2000 | WO2000006167A1 Tricyclic compounds |
| 02/10/2000 | WO2000006147A1 Macrophage scavenger receptor antagonists |
| 02/10/2000 | WO2000006032A1 Ultrasonic enhancement of drug injection |
| 02/10/2000 | WO2000000510A8 Growth factor modulators |
| 02/10/2000 | WO1999063944A3 Novel therapeutic agents that modulate estrogen receptors |
| 02/10/2000 | WO1999061600A3 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 02/10/2000 | CA2339094A1 Macrophage scavenger receptor antagonists |
| 02/10/2000 | CA2338396A1 Ultrasonic enhancement of drug injection |
| 02/10/2000 | CA2338298A1 Tricyclic compounds |
| 02/10/2000 | CA2338019A1 Prostate derived ets factor |
| 02/10/2000 | CA2336536A1 Growth differentiation factor-11 |